KR20190127447A - A composition for preventing and treating oral disease comprising black rice - Google Patents

A composition for preventing and treating oral disease comprising black rice Download PDF

Info

Publication number
KR20190127447A
KR20190127447A KR1020180052077A KR20180052077A KR20190127447A KR 20190127447 A KR20190127447 A KR 20190127447A KR 1020180052077 A KR1020180052077 A KR 1020180052077A KR 20180052077 A KR20180052077 A KR 20180052077A KR 20190127447 A KR20190127447 A KR 20190127447A
Authority
KR
South Korea
Prior art keywords
black rice
composition
rice extract
oral
extract
Prior art date
Application number
KR1020180052077A
Other languages
Korean (ko)
Other versions
KR102097387B1 (en
Inventor
김강주
강주이
유용욱
이운성
이병용
Original Assignee
원광대학교산학협력단
영농조합법인미소드림
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원광대학교산학협력단, 영농조합법인미소드림 filed Critical 원광대학교산학협력단
Priority to KR1020180052077A priority Critical patent/KR102097387B1/en
Publication of KR20190127447A publication Critical patent/KR20190127447A/en
Application granted granted Critical
Publication of KR102097387B1 publication Critical patent/KR102097387B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention can be utilized as a pharmaceutical composition or health functional food by effectively acting on the inflammation inhibitory activity of Aggregatibacter actinomycetemcomitans, pathogen of oral disease, using a black rice extract as an active component.

Description

흑미를 유효성분으로 하는 구강질환 예방 및 치료를 위한 조성물{A composition for preventing and treating oral disease comprising black rice}A composition for preventing and treating oral disease comprising black rice}

본 발명은 치주염을 비롯한 구강질환의 예방 및 치료를 위한 조성물에 관한 발명으로서 보다 상세하게는 흑미를 유효성분으로 하여 구강질환의 원인균인 Aggregatibacter actinomycetemcomitans에 대한 염증억제 활성이 있는 구강질환의 예방 및 치료를 위한 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of oral diseases including periodontitis. More specifically, the black rice is an effective ingredient for the prevention and treatment of oral diseases with inflammatory inhibitory activity against Aggregatibacter actinomycetemcomitans , the causative agent of oral diseases. It relates to a composition for.

구강 건강과 관련하여 전세계적으로 문제가 되고 있는 구강질환은 치아우식증과 치주염이다. WHO의 보고에 따르면 치아우식증과 치주질환은 전세계 성인 인구의 약 60%에서 발병하는 것으로 보고되었다(Petersen, 2003, 2004).Oral diseases, which are a worldwide problem with oral health, are dental caries and periodontitis. WHO reports that dental caries and periodontal disease occur in about 60% of the adult population worldwide (Petersen, 2003, 2004).

이와 같은 구강질환을 일으키는 일차적 원인은 치면세균막 내에 존재하는 세균으로 알려져 있다(Marsh, 1992). 치아우식증은 치면세균막 내에 존재하는 세균들의 당질 대사산물인 젖산 등의 유기산에 의해 치아의 법랑질이 탈회되면서 발생하며, 이러한 세균들 중에서 Streptococcus mutans(S. mutans)Streptococcus sobrinus(S. sobrinus)를 포함하는 뮤탄스 그룹 연쇄상구균(뮤탄스 연쇄상구균)들로 보고되었다(Loesche, 1986). 치주염은 치은연하치면 세균막에 존재하는 Porphyromonas gingivalis(P. gingivalis), Prevotella intermedia(P. intermedia), Aggregatibacter actinomycetemcomitans(A. actinomycetemcomitans), Fusobacterium nucleatum(F. nucleatum) 등의 그람 음성 혐기성 세균 종으로 알려져 있다.The primary cause of oral disease is known as bacteria present in the dental plaque (Marsh, 1992). Dental caries is caused by demineralization of tooth enamel by organic acids such as lactic acid, a sugar metabolite of bacteria present in the dental plaque . Mutans group streptococci (mutans streptococci) have been reported (Loesche, 1986). Periodontitis is known as Gram-negative species such as Porphyromonas gingivalis (P. gingivalis) , Prevotella intermedia (P. intermedia) , Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans), and Fusobacterium nucleatum (F. nucleatum). .

구강 내 세균의 성장을 억제하면서 구강질환을 예방하기 위해 광범위하게 사용되는 화합물로는 클로르헥시딘(chlorhexidine), 불소화합물, xylitol 및 sorbitol 등이 있다. 클로르헥시딘은 그람음성균을 억제하기 위해 치주치료 시 사용되는 항생물질로써, 부작용으로 치아 및 보철물에 착색을 일으키고, 미각 이상 및 구강점막의 작열감을 유발시킨다(Tredwin et al. 2005). 불소화합물은 치아우식증 유발 세균을 억제하기 위해 가장 많이 사용되고 있으나, 과도한 섭취 시 복통과 반점치 및 암을 유발할 수 있다.(Spencer and Do, 2008).Compounds widely used to prevent oral disease while inhibiting the growth of oral bacteria include chlorhexidine, fluorine compounds, xylitol and sorbitol. Chlorhexidine is an antibiotic used in periodontal treatment to inhibit gram-negative bacteria. As a side effect, chlorhexidine causes pigmentation in teeth and prostheses, and causes taste disorders and burning in the oral mucosa (Tredwin et al . 2005). Fluoride compounds are most commonly used to inhibit dental caries-causing bacteria, but excessive intake can cause abdominal pain, spots and cancer (Spencer and Do, 2008).

따라서, 최근에는 상기의 문제점을 해결하기 위해 종래의 구강용 세정작용에 더해 약리작용 및 안정성이 우수한 구강용 조성물이 개발되고 있다.Therefore, recently, in order to solve the above problems, an oral composition having excellent pharmacological action and stability has been developed in addition to the conventional oral cleaning action.

등록번호 10-1641213는 상백피추출물과 화살나무추출물을 유효성분으로 포함하는 치주염 예방 및 치료용 구강조성물에 관한 것으로 치주염 원인균인 포피로모나스 진지바리스(P. gingivalis)의 성장 억제 활성을 나타내고 공개특허공보 10-2011-103267호는 울금잎 추출물을 유효성분으로 하는 충치 또는 치주염 예방 및 치료용 구강 조성물에 관한 것으로 충치 유발균인 스트렙토코커스 뮤턴스(S. mutans)에 대한 항균활성을 나타낸다.Registration No. 10-1641213 relates to an oral composition for preventing and treating periodontitis, including cedar extract and arrow extract as active ingredients, showing growth inhibition activity of P. gingivalis, the cause of periodontitis. 10-2011-103267 relates to an oral composition for the prevention and treatment of caries or periodontitis using turmeric leaf extract as an active ingredient and exhibits antimicrobial activity against S. mutans .

흑미 또는 검정 약쌀은 특유의 색과 향으로 인하여 다양한 형태의 식품으로 가공되고 있으며 소비 또한 증가하고 있다. 흑미에는 항산화성분으로 안토시아닌, 폴리페놀(polyphenol), 플라보노이드(flavonoids), 비타민 등이 많이 포함되어 있다. 흑미의 에탄올 추출물은 항산화 효과가 백미보다 우수하다고 보고되어 있다(Choi SW et al. 1996. Food Biotechnol 5: 305-309, Nam SH et al. 1997. Agri Chem. Biotechnol 40: 307-312). 한편, 쌀배아로 만든 젤리에 흑미 미강 색소를 섞어 흰쥐에 투여하면 혈중 지질대사가 개선되고 항산화 효소 활성이 증가한다는 연구결과(조민경 외, 2008. J Korean Soc. Appl Biol Chem 51(3):200-206)가 있으며, 흑미추출물과 안토시아닌의 일종인 시아니딘은 고콜레스테롤 식이를 투여한 쥐에서 혈중 및 간장의 콜레스테롤 수치를 낮춘다는 것이 보고되어 있다.Black rice or black medicinal rice is processed into various forms of food due to its unique color and aroma, and consumption is also increasing. Black rice contains antioxidants such as anthocyanins, polyphenols, flavonoids, and vitamins. Ethanol extracts of black rice have been reported to have superior antioxidant effects than white rice (Choi SW et al. 1996. Food Biotechnol 5: 305-309, Nam SH et al . 1997. Agri Chem. Biotechnol 40: 307-312). On the other hand, the study showed that the administration of black rice bran pigment to the rats made with rice germ improves lipid metabolism and increases the antioxidant enzyme activity (Cho Min-Kyung et al., 2008. J Korean Soc.Appl Biol Chem 51 (3): 200 -206), black rice extract and anthocyanin have been reported to lower blood and liver cholesterol levels in rats fed a high cholesterol diet.

상기한 효능이 있는 흑미는 종래에 주로 건강기능식품에 주로 적용되어 왔으며, 공개특허공보 제10-2005-0075516호에서 흑미 추출물을 화장품 조성물로 적용한 예가 일부 있으나, 치주염을 비롯한 구강질환의 예방 및 치료 효과 및 이를 위한 조성물의 제조방법 등에 대하여 개시 또는 교시된 바가 없다.The black rice having the above-mentioned efficacy has been mainly applied to the health functional food mainly in the past, and there are some examples of applying the black rice extract as a cosmetic composition in Korean Patent Publication No. 10-2005-0075516, but preventing and treating oral diseases including periodontitis. There is no disclosure or teaching about the effects and methods for preparing the composition therefor.

등록번호 10-1641213, 공개특허공보 10-2011-103267호, 공개특허공보 제10-2005-0075516호Patent Registration No. 10-1641213, Publication No. 10-2011-103267, Publication No. 10-2005-0075516

조민경 외, 2008. J Korean Soc. Appl Biol Chem 51(3):200-206Min-Kyung Cho et al., 2008. J Korean Soc. Appl Biol Chem 51 (3): 200-206 Choi SW et al. 1996. Food Biotechnol 5: 305-309, Nam SH et al. 1997. Agri Chem. Biotechnol 40: 307-312Choi SW et al. 1996. Food Biotechnol 5: 305-309, Nam SH et al. 1997. Agri Chem. Biotechnol 40: 307-312

본 발명은 흑미 추출물을 유효성분으로 한 치주염을 비롯한 구강질환의 치료 및 예방에 효과가 있는 조성물, 건강 기능성 식품 또는 약학 조성물을 제공하는 것을 해결하고자 하는 과제로 삼는다. The present invention is to solve the problem to provide a composition, health functional food or pharmaceutical composition that is effective in the treatment and prevention of oral diseases, including periodontitis, using black rice extract as an active ingredient.

상기한 과제를 해결하기 위하여 본 발명은 흑미 추출물을 유효성분으로 한 구강질환의 예방 및 치료용 조성물, 약제학적 조성물, 건강 기능성 식품을 제공하는 것을 과제 해결을 위한 수단으로 제공한다.In order to solve the above problems, the present invention provides a composition for preventing and treating oral diseases, pharmaceutical compositions, and health functional foods using black rice extract as an active ingredient as a means for solving the problems.

본 발명의 약제학적 조성물, 건강 기능성 식품은 흑미 미강을 에탄올로 추출하여 여과한 후 진공회전 농축기로 농축하는 단계 및 디메틸설폭사이드에 (Dimethylsulfoxide, DMSO)에 용해시키는 단계를 포함하는 것을 특징으로 한다.The pharmaceutical composition of the present invention, the health functional food is characterized in that it comprises the step of extracting black rice bran with ethanol, filtering and concentrating with a vacuum rotary concentrator and dissolving in (dimethylsulfoxide, DMSO) in dimethyl sulfoxide.

본 발명에 따른 흑미 추출물은 치주염 유발균인 A. actinomycetemcomitans에 대한 염증억제 활성이 매우 높을 뿐만 아니라, 구강질환 예방 및 치료용 조성물, 약제학적 조성물 및 건강 기능성 식품 등으로 다양하게 활용될 수 있다.Black rice extract according to the present invention is not only very high inhibitory activity against the periodontitis-inducing bacteria A. actinomycetemcomitans , but also can be used in various compositions such as oral disease prevention and treatment, pharmaceutical compositions and health functional foods.

도 1은 흑미 추출물이 치주염 원인균(A. actinomycetemcomitans)에 의해 유도된 염증성 매개물(NO)을 억제한 결과를 나타내는 도면이다.
도 2 내지 도 4는 흑미 추출물의 치주염 원인균에 의한 염증성 싸이토카인 IL-1β, IL-6, TNF-α 발현 억제효능을 나타내는 도면이다.
1 is a diagram showing the results of black rice extract inhibits the inflammatory mediator (NO) induced by the periodontitis causing bacteria (A. actinomycetem comitans) .
2 to 4 is a view showing the inhibitory effect of inflammatory cytokines IL-1β, IL-6, TNF-α expression by the periodontitis causing bacteria of the black rice extract.

이하 도면과 실시예를 참조하여 본 발명을 보다 상세히 설명한다. Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings and examples.

본 발명은 다양한 변경을 가할 수 있고 여러 가지 실시예를 가질 수 있으나 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.Although the present invention may be modified in various ways and may have various embodiments, the present invention is not intended to be limited to the specific embodiments, and includes all changes, equivalents, and substitutes included in the spirit and technical scope of the present invention. It should be understood to do. In the following description of the present invention, if it is determined that the detailed description of the related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted.

제 1, 제 2 등의 용어는 다양한 구성요소들을 설명하는데 사용될 수 있지만, 상기 구성요소들은 상기 용어들에 의해 한정되어서는 안 된다. 상기 용어들은 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 사용된다. 예를 들어, 본 발명의 권리 범위를 벗어나지 않으면서 제 1 구성요소는 제 2 구성요소로 명명될 수 있고, 유사하게 제 2 구성요소도 제 1 구성요소로 명명될 수 있다. 및/또는 이라는 용어는 복수의 관련된 기재된 항목들의 조합 또는 복수의 관련된 기재된 항목들 중의 어느 항목을 포함한다.Terms such as first and second may be used to describe various components, but the components should not be limited by the terms. The terms are used only for the purpose of distinguishing one component from another. For example, without departing from the scope of the present invention, the first component may be referred to as the second component, and similarly, the second component may also be referred to as the first component. The term and / or includes a combination of a plurality of related items or any item of a plurality of related items.

본 출원에서 사용한 용어는 본 발명을 한정하려는 의도가 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 출원에서, "포함하다" 또는 "가지다" 등의 용어는 명세서상에 기재된 재료, 효과, 효능, 작용기전 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 재료, 효과, 효능, 작용기전 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다. The terms used in the present application are not intended to limit the present invention. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this application, the terms "comprise" or "have" are intended to indicate that there is a material, effect, potency, mechanism of action, or a combination thereof, as described in the specification, including one or more materials, effects, potency, It should be understood that it does not exclude in advance the possibility of the presence or the addition of a mechanism of action or combinations thereof.

다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art. Terms such as those defined in the commonly used dictionaries should be construed as having meanings consistent with the meanings in the context of the related art, and shall not be construed in ideal or excessively formal meanings unless expressly defined in this application. Do not.

실시예 1: 흑미 추출물의 제조Example 1: Preparation of Black Rice Extract

세정하고 건조한 흑미 미강 100g을 1000ml의 95% 에탄올을 추출용매로 사용하여 추출하였다. 추출된 시료를 2호 와트만(Whatman)여과지로 여과하고, 여과된 추출액을 진공회전 농축기로 농축하여 용매성분을 제거한 후, 흑미 추출물을 제조하였다. 100 g of washed and dried black rice bran was extracted using 1000 ml of 95% ethanol as the extraction solvent. The extracted sample was filtered through No. 2 Whatman filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, thereby preparing a black rice extract.

실험예 1: 흑미 추출물의 치주염 원인균 Experimental Example 1: Periodontitis causing bacteria of black rice extract A. actinomyecetemcomitans A. actinomyecetem comitans 에 의한 염증 억제효능 측정Inhibition of inflammation by

흑미 추출물의 항염증 활성을 측정하기 위하여 대식세포(RAW264.7) 를 각 well당 5 ×105 cells/ml 씩 24-well plate에 분주하여 37℃, 5% CO₂ 배양기에서 24시간 동안 배양 하였다. 그런 다음 실시예 1에 의하여 제조된 흑미 추출물 0, 0.0625, 0.125, 0.25, 1, 2 mg/ml을 전처리한 후, 0.5% formal saline 처리한 Aggregatibacter actinomyecetemcomitans (A. actinomycetemcomitans) 1 ×108 cfu를 투여 후, 24시간 동안 배양하였다. 24시간 배양 후 상청액 100㎕ 씩 96well plate에 분주하고, nitric oxide(NO)의 농도를 측정하기 위하여 Griess reagent로 반응시키고, ELISA reader로 540 nm 에서 흡광도를 측정한 후, NO 표준곡선을 이용하여 NO 농도를 구하였다.To measure the anti-inflammatory activity of the black rice extract, macrophages (RAW264.7) were dispensed in 24-well plates at 5 x 10 5 cells / ml per well and incubated in a 37 ° C, 5% CO₂ incubator for 24 hours. Then, after pretreatment with 0, 0.0625, 0.125, 0.25, 1, 2 mg / ml black rice extract prepared in Example 1, 0.5 × formal saline treated Aggregatibacter actinomyecetemcomitans ( A. actinomycetemcomitans) 1 × 10 8 cfu Then, incubated for 24 hours. After incubation for 24 hours, 100 μl of supernatant was dispensed into a 96well plate, reacted with a Griess reagent to measure nitric oxide (NO) concentration, and absorbance at 540 nm was measured using an ELISA reader. The concentration was obtained.

A. actinomycetemcomitans(A. a.) NO 억제율은 다음과 같이 계산하였다. A. actinomycetem comitans (A. a.) NO inhibition was calculated as follows.

NO 억제율 = 1 -

Figure pat00001
×100 % NO inhibition rate = 1-
Figure pat00001
× 100%

1) A. a. : A. actinomycetemcomitans 1) A. a. : A. actinomycetemcomitans

그 결과를 표 1과 도 1을 통해 도시하였다. 그 결과 대조군에서는 NO 농도가 8.22 ±0.00 μM이었으며, 흑미 추출물 단독투여군 0.0625 mg/ml에서는 8.12±0.00 μM, 0.125 mg/ml에서는 7.56±0.00 μM, 0.25 mg/ml에서는 8.03±0.00 μM, 0.5 mg/ml에서는 7.51±0.00 μM, 1 mg/ml에서는 8.12±0.00 μM, 2 mg/ml에서는 7.99±0.00 μM, 보였고 A. actinomycetemcomitans 단독투여군 에서는 NO 농도가 18.53±0.00 μM으로 상승하였고, A. actinomycetemcomitans + 흑미 추출물 0.0625 mg/ml에서는 17.68±0.00 μM, 0.125 mg/ml에서는 18.01±0.00 μM, 0.25 mg/ml에서는 18.48±0.00 μM, 0.5 mg/ml에서는 16.92±0.00 μM, 1 mg/ml에서는 13.42±0.00 μM, 2 mg/ml에서는 9.45±0.00 μM을 보였다. The results are shown in Table 1 and FIG. As a result, NO concentration was 8.22 ± 0.00 μM in the control group, 8.12 ± 0.00 μM in the 0.0625 mg / ml black rice extract alone group, 7.56 ± 0.00 μM in the 0.125 mg / ml, 8.03 ± 0.00 μM in the 0.25 mg / ml, 0.5 mg / ml 7.51 ± 0.00 μM in ml, 8.12 ± 0.00 μM in 1 mg / ml, 7.99 ± 0.00 μM in 2 mg / ml, and the NO concentration rose to 18.53 ± 0.00 μM in the A. actinomycetemcomitans alone group and A. actinomycetemcomitans + black rice Extract 17.68 ± 0.00 μM at 0.0625 mg / ml, 18.01 ± 0.00 μM at 0.125 mg / ml, 18.48 ± 0.00 μM at 0.25 mg / ml, 16.92 ± 0.00 μM at 0.5 mg / ml, 13.42 ± 0.00 μM at 1 mg / ml , 2 mg / ml showed 9.45 ± 0.00 μM.

흑미 추출물이 치주염균에 의해 유도된 염증성 매개물 (NO)의 억제Black Rice Extract Inhibits Inflammatory Mediator (NO) Induced by Periodontitis 시료sample Nitiric oxide(μM)Nitrile oxide (μM) 억제율(%)% Inhibition 음성대조군 Negative Control 8.22±0.00 8.22 ± 0.00 -- 1One 흑미 추출물 0.0625(mg/ml) Black Rice Extract 0.0625 (mg / ml) 8.12±0.00 8.12 ± 0.00 -- 22 흑미 추출물 0.125(mg/ml) Black Rice Extract 0.125 (mg / ml) 7.56±0.00 7.56 ± 0.00 -- 33 흑미 추출물 0.25(mg/ml) Black Rice Extract 0.25 (mg / ml) 8.03±0.00 8.03 ± 0.00 -- 44 흑미 추출물 0.5(mg/ml) Black Rice Extract 0.5 (mg / ml) 7.51±0.00 7.51 ± 0.00 -- 55 흑미 추출물 1(mg/ml) Black Rice Extract 1 (mg / ml) 8.12±0.00 8.12 ± 0.00 -- 66 흑미 추출물 2(mg/ml) Black Rice Extract 2 (mg / ml) 7.99±0.00 7.99 ± 0.00 -- 77 A. a.1) 단독 투여군A. a. 1) single administration group 18.53±0.0018.53 ± 0.00 -- 88 A. a. + 흑미 추출물 0.0625(mg/ml) A. a. + Black Rice Extract 0.0625 (mg / ml) 17.68±0.00*17.68 ± 0.00 * 8.25%8.25% 99 A. a. + 흑미 추출물 0.125(mg/ml) A. a. + 0.125 mg / ml black rice extract 18.01±0.00*18.01 ± 0.00 * 5.04%5.04% 1010 A. a. + 흑미 추출물 0.25(mg/ml) A. a. + Black rice extract 0.25 (mg / ml) 18.48±0.00*18.48 ± 0.00 * 0.45%0.45% 1111 A. a. + 흑미 추출물 0.5(mg/ml) A. a. + Black Rice Extract 0.5 (mg / ml) 16.92±0.00*16.92 ± 0.00 * 15.59%15.59% 1212 A. a. + 흑미 추출물 1(mg/ml) A. a. + Black Rice Extract 1 (mg / ml) 13.42±0.00*13.42 ± 0.00 * 49.54%49.54% 1313 A. a. + 흑미 추출물 2(mg/ml) A. a. + Black Rice Extract 2 (mg / ml) 9.45±0.00* 9.45 ± 0.00 * 88.07%88.07% 1) A. a. : A. actinomycetemcomitans 1) A. a. : A. actinomycetemcomitans

실험예 2: 흑미 추출물의 싸이토카인의 발현에 미치는 영향 측정 방법 및 결과Experimental Example 2: Method and result of measuring the effect of black rice extract on the cytokine expression

흑미 추출물 항염증 싸이토카인을 측정하기 위하여 대식세포 (RAW264.7)를 각 well당 2 ×105 cells/ml 씩 60m dish에 분주하여 37℃, 5% CO₂배양기에서 24시간 동안 배양 하였다. 실시예 1에 의하여 제조된 흑미 추출물 0, 1, 2 mg/ml을 전처리한 후, 0.5% formal saline 처리한 치주염 원인균 A. actinomycetemcomitans 1 ×108 cfu를 투여 후, 24시간 동안 배양하였다. Trizol처리 후 RNA를 추출하여 Real-time PCR 로 IL-1β, IL-6, TNF-α(표 2참조)의 발현을 측정하였다. 그 결과를 표 3와 도 2를 통해 도시하였다. In order to measure anti-inflammatory cytokines of black rice extract, macrophages (RAW264.7) were dispensed in a 60m dish at 2 × 10 5 cells / ml for each well and incubated in a 37 ° C., 5% CO₂ incubator for 24 hours. After pretreatment with 0, 1, 2 mg / ml of black rice extract prepared in Example 1, 0.5% formal saline-treated periodontal causative agent A. actinomycetemcomitans 1 × 10 8 cfu was incubated for 24 hours. After trizol treatment, RNA was extracted and the expression of IL-1β, IL-6, and TNF-α (see Table 2) was measured by real-time PCR. The results are shown in Table 3 and FIG.

그 결과 치주염 원인균만 처리했을 때는 대조군에 비하여 IL-1β는 90.39 ±8.45, IL-6897.15 ±75.38, TNF-α 5.92 ±0.55 의 발현이 증가함을 보였으나, 흑미 추출물을 2mg/ml 농도로 투여 했을 때 치주염 원인균에 의해 유도된 IL-1β는 2.25 ±0.56, IL-6는 0.86 ±0.86, TNF-α0.34 ±0.08로 발현이 억제됨을 확인할 수 있었다. As a result, IL-1β showed increased expression of 90.39 ± 8.45, IL-6897.15 ± 75.38, and TNF-α 5.92 ± 0.55 when only periodontal causative organisms were treated, but black rice extract was administered at 2mg / ml concentration. When IL-1β induced by periodontal causative bacteria was 2.25 ± 0.56, IL-6 0.86 ± 0.86, TNF-α 0.34 ± 0.08 was confirmed that the expression is suppressed.

Primer Sequences of inflammatory genes Primer Sequences of inflammatory genes Gene Gene Primer sequencePrimer sequence IL-1βIL- ForwardForward 5′-GAAAGACGGCACACCCACCCT-3′5′-GAAAGACGGCACACCCACCCT-3 ReverseReverse 5′-GCTCTGCTTGTGAGGTGCTGATGTA-3′5′-GCTCTGCTTGTGAGGTGCTGATGTA-3 ′ IL-6IL-6 ForwardForward 5′-TCAGAATTGCCATTGCACA-3′5′-TCAGAATTGCCATTGCACA-3 ReverseReverse 5′-GTCGGAGGCTTAATTACACATG-3′5′-GTCGGAGGCTTAATTACACATG-3 ′ TNF-αTNF-α ForwardForward 5′-GGCAGGTCTACTTTGGAGTCATTGC-3′5′-GGCAGGTCTACTTTGGAGTCATTGC-3 ReverseReverse 5′-ACATTCGAGGCTCCAGTGAATTCGG-3′5′-ACATTCGAGGCTCCAGTGAATTCGG-3 ′ β-actinβ-actin ForwardForward 5′-CATCACTATCGGCAATGAGC-3′5′-CATCACTATCGGCAATGAGC-3 ReverseReverse 5′-GACAGCACTGTGTTGGCATA-3′5′-GACAGCACTGTGTTGGCATA-3 ′

흑미 추출물이 치주염균에 의해 유도된 염증성 싸이토카인 IL-1β, IL-6, TNF-α 발현 억제효능Black Rice Extract Inhibits the Expression of Inflammatory Cytokines IL-1β, IL-6, and TNF-α Induced by Periodontitis Real-Time PCR(gene expression folds of control)Real-Time PCR (gene expression folds of control) SampleSample
Primer CytokinesPrimer Cytokines
ControlControl A.a.A.a. 1) One) 단독투여Alone A.a.+흑미(2mg/ml)A.a. + black rice (2 mg / ml)
IL - βIL-β 1 ±0.551 ± 0.55 90.39 ±8.4590.39 ± 8.45 2.25 ±0.56*2.25 ± 0.56 * IL - 6IL-6 1 ±0.691 ± 0.69 897.15 ±75.38897.15 ± 75.38 0.86 ±0.86*0.86 ± 0.86 * TNF - αTNF-α 1 ±0.61 1 ± 0.61 5.92 ±0.555.92 ± 0.55 0.34 ±0.08*0.34 ± 0.08 *

1) A. a. : A. actinomycetemcomitans 1) A. a. : A. actinomycetemcomitans

상기한 실험예를 통해 본 발명의 흑미 추출물은 치주염 원인균인 A. actinomyecetemcomitans의 발현을 억제하여 치주염을 비롯한 구강질환 예방과 치료에 매우 효과적임을 알 수 있다. Through the above experimental example, it can be seen that the black rice extract of the present invention is very effective in preventing and treating oral disease including periodontitis by inhibiting the expression of A. actinomyecetemcomitans , which is the cause of periodontitis.

상기한 흑미 추출물은 구강 조성물 또는 기능성 건강식품으로 제조할 수 있다. 보다 구체적으로 구강 조성물은 불화나트륨, 에탄올, 글리세린, 구연산, 페퍼민트를 함유한 구강 청정제로 제조할 수 있고, 솔비톨액, 글리세린, 프로필렌글리콜, 지방산에스테르, 알킬황산나트륨, 염화나트륨, 향료, 카르복실메틸셀롤로즈나트륨을 함유한 치약으로 제조될 수 있으며, 설탕, 포도당, 전분, 글리세린, 향료를 함유하여 츄잉껌으로 제조 가능하다. The black rice extract can be prepared by oral composition or functional health food. More specifically, oral compositions can be prepared with oral detergents containing sodium fluoride, ethanol, glycerin, citric acid and peppermint, sorbitol solution, glycerin, propylene glycol, fatty acid esters, sodium sulfate, sodium chloride, flavorings, carboxymethylcellulose It may be prepared as a toothpaste containing sodium, and may be prepared as chewing gum by containing sugar, glucose, starch, glycerin, and flavorings.

기능성 건강식품은 상기한 흑미 추출물에 비타민, 비오틴, 니코틴산아미드, 엽산, 칼슘, 무기질 혼합물, 산화아연, 칼륨, 구연산나트륨, 염화마그네슘을 혼합하여 제조할 수 있다. Functional health foods can be prepared by mixing the above black rice extract with vitamins, biotin, nicotinic acid amide, folic acid, calcium, mineral mixtures, zinc oxide, potassium, sodium citrate, magnesium chloride.

지금까지 예시적인 실시 태양을 참조하여 본 발명을 기술하여 왔지만, 본 발명의 속하는 기술 분야의 당업자는 본 발명의 범주를 벗어나지 않고서도 다양한 변화를 실시할 수 있으며 그의 요소들을 등가물로 대체할 수 있음을 알 수 있을 것이다.While the invention has been described with reference to exemplary embodiments so far, those skilled in the art will appreciate that various changes can be made therein and equivalents may be substituted for elements thereof without departing from the scope of the invention. You will know.

또한, 본 발명의 본질적인 범주를 벗어나지 않고서도 많은 변형을 실시하여 특정 상황 및 재료를 본 발명의 교시내용에 채용할 수 있다. 따라서, 본 발명이 본 발명을 실시하는데 계획된 최상의 양식으로서 개시된 특정 실시 태양으로 국한되는 것이 아니며, 본 발명이 첨부된 특허청구의 범위에 속하는 모든 실시 태양을 포함하는 것으로 해석되어야 한다.In addition, many modifications may be made to adapt a particular situation and material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the present invention not be limited to the particular embodiments disclosed as the best mode contemplated for carrying out the invention, but that the invention will include all embodiments falling within the scope of the appended claims.

본 발명의 흑미 추출물은 치아 건강을 위한 약제학적 조성물 및 건강 기능성 식품 등으로 다양하게 활용이 가능하다.Black rice extract of the present invention can be utilized in various ways, such as pharmaceutical compositions and health functional food for dental health.

Claims (3)

흑미 추출물을 유효성분으로 한 구강질환의 예방 및 치료를 위한 조성물.
Composition for the prevention and treatment of oral diseases with black rice extract as an active ingredient.
제 1항에 있어서,
상기 구강질환은 그 유발균이 Aggregatibacter actinomycetemcomitans인 것을 특징으로 하는 구강질환의 예방 및 치료용 조성물.
The method of claim 1,
The oral disease is a composition for the prevention and treatment of oral diseases, characterized in that the causing bacteria Aggregatibacter actinomycetemcomitans .
흑미 미강을 에탄올로 추출하는 단계;
상기 추출된 흑미 미강을 여과한 후 진공회전 농축기로 농축하는 단계; 및
상기 농축된 용액의 용매성분을 제거한 후, 디메틸설폭사이드 (DMSO)에 용해시키는 단계를 포함하는 것을 특징으로 한 구강질환의 예방 및 치료용 조성물을 제조하는 방법.




Extracting the black rice bran with ethanol;
Filtering the extracted black rice bran and concentrating with a vacuum rotary concentrator; And
After removing the solvent component of the concentrated solution, the method for producing a composition for the prevention and treatment of oral diseases comprising the step of dissolving in dimethyl sulfoxide (DMSO).




KR1020180052077A 2018-05-04 2018-05-04 A composition for preventing and treating oral disease comprising black rice KR102097387B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020180052077A KR102097387B1 (en) 2018-05-04 2018-05-04 A composition for preventing and treating oral disease comprising black rice

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180052077A KR102097387B1 (en) 2018-05-04 2018-05-04 A composition for preventing and treating oral disease comprising black rice

Publications (2)

Publication Number Publication Date
KR20190127447A true KR20190127447A (en) 2019-11-13
KR102097387B1 KR102097387B1 (en) 2020-04-06

Family

ID=68535304

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180052077A KR102097387B1 (en) 2018-05-04 2018-05-04 A composition for preventing and treating oral disease comprising black rice

Country Status (1)

Country Link
KR (1) KR102097387B1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050106710A (en) * 2004-05-06 2005-11-11 주식회사 태평양 A composition for skin external application
KR101604448B1 (en) * 2014-05-13 2016-03-21 농업회사법인 잠(유) Pharmaceutical composition for antiinflammatory and preventing or treating immune disease comprising extract of black rice bran
KR101641213B1 (en) 2015-07-08 2016-07-20 대한민국(환경부 국립생물자원관장) Oral composition comprising Morus alba L. extract and Winged spindle extract for preventing and treating periodontal disease
KR20160139170A (en) * 2015-05-27 2016-12-07 농업회사법인 잠(유) Manufacturing Method of Extracts Powder of Black Rice Bran And Extracts Powder of Black Rice Bran By The Same
KR20160149049A (en) * 2015-06-17 2016-12-27 대한민국(농촌진흥청장) Pharmaceutical composition for preventing or treating osteoporosis comprising an extract of black rice aleurone layer
KR101736826B1 (en) * 2015-05-28 2017-05-18 농업회사법인 잠(유) Pharmaceutical composition for improving immune comprising extract powder of black rice bran and its manufacturing method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050106710A (en) * 2004-05-06 2005-11-11 주식회사 태평양 A composition for skin external application
KR101604448B1 (en) * 2014-05-13 2016-03-21 농업회사법인 잠(유) Pharmaceutical composition for antiinflammatory and preventing or treating immune disease comprising extract of black rice bran
KR20160139170A (en) * 2015-05-27 2016-12-07 농업회사법인 잠(유) Manufacturing Method of Extracts Powder of Black Rice Bran And Extracts Powder of Black Rice Bran By The Same
KR101736826B1 (en) * 2015-05-28 2017-05-18 농업회사법인 잠(유) Pharmaceutical composition for improving immune comprising extract powder of black rice bran and its manufacturing method
KR20160149049A (en) * 2015-06-17 2016-12-27 대한민국(농촌진흥청장) Pharmaceutical composition for preventing or treating osteoporosis comprising an extract of black rice aleurone layer
KR101641213B1 (en) 2015-07-08 2016-07-20 대한민국(환경부 국립생물자원관장) Oral composition comprising Morus alba L. extract and Winged spindle extract for preventing and treating periodontal disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Choi SW et al. 1996. Food Biotechnol 5: 305-309, Nam SH et al. 1997. Agri Chem. Biotechnol 40: 307-312
조민경 외, 2008. J Korean Soc. Appl Biol Chem 51(3):200-206

Also Published As

Publication number Publication date
KR102097387B1 (en) 2020-04-06

Similar Documents

Publication Publication Date Title
KR101520188B1 (en) Composition for preventing or treating oral disease comprising toosendanin
KR100835899B1 (en) Composition comprising zingiber officinale roscoe or gingerol isolated from the same for preventing or treating periodontitis
Jain et al. Liquorice root extracts as potent cariostatic agents in pediatric practice
WO2018062605A1 (en) Toothpaste composition containing galenical extract
JP6514684B2 (en) Oral bacterial growth inhibitor
KR20190000955A (en) Composition for preventing or treating periodontal disease comprising extracts of herbal mixture
JP4112730B2 (en) Antibacterial agent for oral cavity
KR101225114B1 (en) Composition for whitenings and treating skin damage or disease comprising bee venom
KR20160088841A (en) Composition for preventing or treating oral disease comprising Emodin
KR20170141053A (en) Composition for prevention or treatment of dental disease comprising an extract of Gardenia jasminoides
KR102207872B1 (en) Oral composition for preventation or treatment of oral disease
KR102097387B1 (en) A composition for preventing and treating oral disease comprising black rice
KR20170141034A (en) Composition for prevention or treatment of dental disease comprising Panax ginseng extract
KR20170141030A (en) Composition for prevention or treatment of dental disease comprising cistanoside A
KR20220099175A (en) Oral composition comprising herbal complex
KR101574678B1 (en) Composition for preventing or treating periodontal disease comprising Lactuca scariola extract as effective component
KR101630829B1 (en) Composition for preventing or treating oral disease comprising Echinacoside
KR102260939B1 (en) Composition for prevention or treatment of dental disease comprising an extract of Matteuccia struthiopteris
KR102439853B1 (en) Compositions for preventing or treating periodontal disease comprising extract of maple
KR101596438B1 (en) Composition for preventing or treating oral disease comprising Glabridin
KR102471629B1 (en) Composition for preventing or treating inflammatory diseases comprising extracts of Acorus gramineus and Dendropanax morbifera
KR102313657B1 (en) Composition for preventing or treating oral diseases containing Ecklonia cava extract
KR20120049488A (en) Pharmaceutical and food composition for preventing or treating cavity and periodontal disease comprising extract of yacon as effective component
KR20170134123A (en) Composition for prevention or treatment of dental disease comprising astragaloside
KR20170141057A (en) Composition for prevention or treatment of dental disease comprising an extract of Daphne genkwa

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant